Sweden's BioInvent posts lower net sales in Q4, focuses on  accelerating advanced assets

BioInvent International AB

26/02/2026 07:23

Overview

The Swedish biotech firm's Q4 net sales fell significantly yr/yr

Adjusted EPS for Q4 showed a loss

Company focused on accelerating advanced assets, pausing earlier programs

Outlook

BioInvent prioritizes BI-1808 and BI-1206 for accelerated development in 2025

Company sees potential in BI-1808 and pembrolizumab combination for ovarian cancer

BioInvent aims to enhance value creation through strategic portfolio changes

Result Drivers

CLINICAL FOCUS - BioInvent sharpened clinical focus on BI-1808 and BI-1206, pausing earlier programs to maximize success and near-term value creation, per CEO Martin Welschof

PROMISING TRIAL DATA - Promising Phase 2a data for BI-1808 in TCL and BI-1206 in NHL presented at ASH 2025

REGULATORY ACHIEVEMENTS - BI-1808 received Orphan Drug Designation from EMA and FDA, enhancing focus on advanced clinical programs

Company press release: ID:nMFNYXYwv

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 3 mln
Q4 Adjusted EPS
-SEK 1.91
Q4 Net Income
-SEK 125.80 mln
Q4 Adjusted Free Cash Flow
-SEK 90.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for BioInvent International AB is SEK80.00, about 204.2% above its February 25 closing price of SEK26.30

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)